Long-Term Follow-Up from CheckMate 214 in Advanced RCC : com

The expert panel discusses the 8-year follow-up data from CheckMate 214 looking at nivolumab plus ipilimumab in first-line advanced RCC and provide clinical insights on treatment decisions.

Related Keywords

, Advanced Renal Cell Carcinoma , Term Follow Up , Renal Cell Carcinoma , Nrcc , Advanced Rcc , Checkmate 214 , Nivolumab , Ipilimumab , Metastatic Clear Cell Rcc , Ctla4 Inhibition , Ctla4 , Metastatic Clear Cell Renal Carcinoma ,